Publication date context 2026-02-19T14:30:49Z. Meta description Regulatory update on StimLabs dehydrated umbilical cord particulate used with the Corplex P wound care device in chronic ulcers and diabetic foot ulcers. This article summarizes a case series described by StimLabs and notes the device use to cover, protect and maintain a moist wound environment. The sponsor is StimLabs and the trial status is not yet recruiting. The information is drawn from ClinicalTrials.gov listing NCT07414368 and related materials provided by the sponsor. For context note related reading includes Regulatory update on wound care devices and Umbilical cord based products in wound care. Official trial information is available at ClinicalTrials.gov entry NCT07414368.
What is Corplex P and how is it used in this study?
The source text describes a device named Corplex P. It is described as being used to cover wounds and to protect the wound bed while maintaining a moist environment. The product is associated with dehydrated human umbilical cord particulate as part of the wound care approach under study. The chronic ulcer and diabetic foot ulcer indications are listed in the trial context. The intervention is described as applying the device to the wound to preserve a moist environment that supports healing and provides a barrier against contamination.
What changed in trial status and what safety or regulatory considerations arise?
The listing notes not yet recruiting for the study. Sponsor is StimLabs. The record is placed on ClinicalTrials.gov with subject matter in wound care using a human derived biomaterial. The MDR oriented language would require clear intended use, performance claims, and safety statements. At this stage the report does not provide results or evidence of effectiveness. Stakeholders should monitor updates for safety signals and post market claims and ensure alignment with regulatory exemptions or approvals as applicable.
What are the regulatory implications for this wound care product?
Under MDR Annex XIV the manufacturer must specify the device class, intended purpose, performance claims and safety measures. The source frames the Corplex P as a cover and moisture maintaining device using dehydrated umbilical cord particulate. The content underscores that statements regarding safety or effectiveness must be supported by robust clinical data. As a not yet recruiting listing tied to a device claim, any marketed material should be clearly labeled and avoid unauthenticated claims. This context informs how the sponsor and any future reports should handle regulatory submissions and post market obligations.
What is the clinical context for chronic ulcers and diabetic foot ulcers as described?
Chronic ulcers and DFU are among the conditions listed. The clinical need in these conditions includes persistent wounds with risk of infection and poor healing. The case series centers on a product designed to support moist wound healing. Regulatory teams should consider how labeling and trial reporting align with wound care device guidance and evidence requirements. The study’s early stage means results are not yet available to confirm effectiveness. Clinicians and regulators should follow the official updates and the ClinicalTrials.gov entry for the most current information and definitions of endpoints.
What are the next steps for evidence generation and regulatory submission?
The next steps likely include data collection from ongoing or planned studies and potentially expanded trials. The sponsor will need to provide clear safety and performance data that supports an intended use claim consistent with MDR. Future reports should present patient outcomes, adverse event data, and comparative analysis if available. Stakeholders should prepare for labeling changes and potential regulatory submissions if the evidence supports marketing claims beyond the current description. The ClinicalTrials.gov listing will be the primary source for updates while the sponsor publishes results and regulatory documents.
FAQ
- 1. What is Corplex P?
Answer: Corplex P is described as a device to cover wounds and maintain a moist healing environment using dehydrated umbilical cord particulate. The description is limited to regulatory style information and the intended use described by the sponsor. - 2. What does not yet recruiting mean for stakeholders?
Answer: It indicates that no participants are currently enrolled and that the study is in an early stage. Regulatory obligations remain and any claims must be supported by subsequent data. - 3. Where can I find official trial information?
Answer: See the ClinicalTrials.gov listing NCT07414368 for updates and endpoints.
In summary this article outlines a not yet recruiting case series involving dehydrated human umbilical cord particulate and a wound covering device. The content highlights the regulatory framing that any marketing statements must be backed by evidence and that the sponsor should provide clear safety and performance data. Readers should watch for updates through official trial records and regulatory filings.
This article is for professionals and informational purposes only and does not constitute legal advice. It reflects the information available from the source text and does not replace official regulatory guidance.
For full information about the announcement see the line below.
https://clinicaltrials.gov/study/NCT07414368?term=medical+device